Bifidobacterium capable of relieving atopic dermatitis and its application

A bifidobacterium and bifidobacterium breve technology, applied in the field of microbiology, can solve the problems of difficult treatment of atopic dermatitis, poor tolerance of AD patients, life troubles of AD patients, etc., to improve skin pathological symptoms and mast cell infiltration, The effect of improving the degree of ear swelling and less adverse reactions

Active Publication Date: 2022-02-01
JIANGNAN UNIV
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the above-mentioned drugs, especially the hormonal drugs, all have relatively large adverse reactions, which not only brings great difficulties to the treatment of atopic dermatitis, but also brings great difficulties to the lives of AD patients. In addition, these drugs are poorly tolerated by individual AD patients, and many patients with multiple relapses may face the dilemma of no available drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bifidobacterium capable of relieving atopic dermatitis and its application
  • Bifidobacterium capable of relieving atopic dermatitis and its application
  • Bifidobacterium capable of relieving atopic dermatitis and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0090] Example 1-1: Screening and strain identification of Bifidobacterium breve

[0091] 1. Screening

[0092] Take healthy human feces from Chaoyang District, Beijing as a sample. After the sample is pretreated, draw 0.5mL from the mixed sample and add it to 4.5mL sterile water. Acid) for gradient dilution, select the appropriate gradient dilution to spread on the MRS solid medium (containing 0.05% cysteine), cultivate at 37°C for 48h, pick typical colonies to streak and purify on the MRS solid medium, A single colony was picked and transferred to MRS liquid medium (containing 0.05% cysteine) for enrichment and preserved in 30% glycerol to obtain strain CCFM1067 (original number BJCY3M3), strain FFJND14L2 and strain AHWH11M1.

[0093] 2. Identification

[0094] The genomes of CCFM1067, FFJND14L2, and AHWH11M1 were extracted, and the 16S rDNA of CCFM1067, FFJND14L2, and AHWH11M1 were amplified and sequenced. The amplified nucleotide sequences of the 16S rDNA of CCFM1067, FF...

Embodiment 1-2

[0095] Example 1-2: Colonies of Bifidobacterium breve

[0096] After inoculating Bifidobacterium breve CCFM1067 into MRS solid medium (containing 0.05% cysteine) and culturing at 37°C for 48 hours, the colonies were observed and found that the colonies were convex to cushion-like, and the surface was smooth or wavy , soft texture.

[0097] Bifidobacterium breve (Bifidobacterium breve) CCFM1067 was inserted into MRS liquid medium (containing 0.05% cysteine) and anaerobically cultured at 37°C for 24 h, then transferred to fresh MRS liquid medium (containing 0.05% cysteine). acid), cultivated under the same conditions for 24 hours, centrifuged the cells at 6000 g for 15 min, washed the cells with 0.9% normal saline and centrifuged again at 6000 g for 10 min to obtain the cells, resuspended with 30% sucrose solution, and frozen at -80°C until use.

Embodiment 1-3

[0098] Example 1-3: Effects of different Bifidobacteria breve on ear thickness of mice with atopic dermatitis

[0099] Thirty 6-week-old healthy female C57BL / 6 mice were randomly divided into 6 groups, with 5 mice in each group. The 6 groups were: blank group (Control), administration of 2,4-dinitrofluorobenzene (2, 4-dinitrofluorobenzene, DNFB) model group (DNFB), positive drug group (Keto) administered with ketotifen, BR1 group administered with Bifidobacterium breve CCFM1067, BR2 group administered with Bifidobacterium breve FFJND14L2, administered with The BR3 group of Bifidobacterium breve AHWH11M1, wherein, BR1 group, BR2 group and BR3 group are all treatment groups.

[0100] The experiment lasted for four weeks: the first week was the adaptation period of the mice; the second week began to gavage the mice until the end of the experiment, and the treatment group was gavaged with B. The total amount of live bacteria is 1×10 9CFU) / only / time dosage is carried out intragas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a bifidobacterium capable of relieving atopic dermatitis and an application thereof, and belongs to the technical field of microbes and the technical field of medicine. Bifidobacterium breve CCFM1067, Bifidobacterium adolescentis CCFM1066 and Bifidobacterium bifidum CCFM1063 of the present invention can prevent and / or treat atopic dermatitis, therefore, Bifidobacterium breve CCFM1067 of the present invention, Bifidobacterium adolescentis CCFM1066 and two Bifidobacterium fidgetum CCFM1063 has a great application prospect in the preparation of products (such as food or medicine) for the prevention and / or treatment of atopic dermatitis.

Description

technical field [0001] The invention relates to a bifidobacterium capable of relieving atopic dermatitis and an application thereof, belonging to the technical field of microbes and the technical field of medicine. Background technique [0002] Atopic dermatitis (AD), also known as atopic eczema and atopic dermatitis, is a chronic, relapsing, inflammatory skin disease accompanied by repeated itching. [0003] Atopic dermatitis has gradually developed into a global disease. Epidemiological surveys show that the prevalence of atopic dermatitis is increasing year by year. Currently, Australia reports that the incidence of AD in school-age children is 9.6-13.3%. In children in the United States and the United Kingdom, the prevalence of AD reaches approximately 20%. The incidence of AD in Danish children and adolescents increased from 17.3% to 27.3% during the 15 years from 1986 to 2001. A survey in 1998 showed that 0.7% of patients with AD in the age group of 6 to 20 years ol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/745A61P17/00A61P37/08A23L33/135A23L19/20A23C9/12A23L11/65C12R1/01
CPCA61K35/745A61P17/00A61P37/08A23L33/135A23L19/20A23C9/1203A23C11/106A23V2002/00C12R2001/01C12N1/205A23V2400/513A23V2400/517A23V2400/519A23V2200/318
Inventor 陆文伟陈卫方志锋翟齐啸田丰伟崔树茂唐鑫毛丙永赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap